Background and objective No clinical trial has examined the risk of infection associated
methotrexate and azathioprine, two advocated treatments for sarcoidosis. We aimed to …

Serious infections impair quality of life and increase costs. Our aim was to determine if
sarcoidosis is associated with a higher rate of serious infection and whether this varies by …

Background Steroids remain the first-choice therapeutic in sarcoidosis; however, long-term
use is associated with toxicity. Evidence defining the best second-line therapeutic is …

Rationale: Patients with sarcoidosis may have an increased risk of infection similar to other
immune-mediated disorders. However, the data are still limited. Objectives: To investigate …

Currently prednisone is the first-line pharmacological treatment option for pulmonary
sarcoidosis. Methotrexate is used as second-line therapy and seems to have fewer side …

Background: Methotrexate (MTX) is a second line agent for treatment of sarcoidosis. Its long
term safety and efficacy in sarcoidosis remains unclear. Methods: This was a retrospective …

Background Treatment of pulmonary sarcoidosis is recommended in case of significant
symptoms, impaired or deteriorating lung function. Evidence-based treatment …

Objective Methotrexate (MTX) is a cytotoxic agent that is commonly employed as an
alternative to corticosteroids to treat sarcoidosis, although the proper use and efficacy of …

Background During the last few years, investigators have debated the role that infectious
agents may have in sarcoidosis pathogenesis. With the emergence of new molecular …

Background and objective The aims of this national cohort study were:(1) to evaluate
mortality in patients with sarcoidosis, stratified by gender, age and systemic corticosteroid …